Glycopeptide Antibiotics Global Market Report 2024

Description

“Glycopeptide Antibiotics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glycopeptide antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glycopeptide antibiotics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The glycopeptide antibiotics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug: Vancomycin; Dalbavancin; Oritavancin; Other Drugs
2) By Route of Administration: Oral; Parenteral; Other Routes
3) By Indication: Skin And Structure Infection; Meningitis; Clostridioides Difficile Infection; Enterocolitis; Other Indications
4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Companies Mentioned: ANI Pharmaceuticals Inc.; Fresenius SE & Co. KGaA; Pfizer Inc.; Mylan N.V.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Glycopeptide antibiotics constitute a category of antibiotics characterized by structures that include a glycosylated cyclic or polycyclic non-ribosomal peptide, and they are employed to impede the formation of bacterial cell walls. These antibiotics were initially discovered in plant and soil bacteria.

The primary drugs within the glycopeptide antibiotics class include vancomycin, dalbavancin, oritavancin, and others. Vancomycin, for example, is a member of the glycopeptide antibiotics family, recognized for its ability to eliminate microorganisms in the intestines. It is used in the treatment of colitis, a condition that can develop after antibiotic therapy. These drugs are administered through oral, parenteral, and other routes for the treatment of various conditions such as skin and structure infections, meningitis, Clostridioides difficile infection, enterocolitis, and more. The end-users of these antibiotics include hospitals, specialty clinics, home care, and other healthcare providers.

The glycopeptide antibiotics market research report is one of a series of new reports from The Business Research Company that provides glycopeptide antibiotics market statistics, including glycopeptide antibiotics industry global market size, regional shares, competitors with a glycopeptide antibiotics market share, detailed glycopeptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the glycopeptide antibiotics industry. This glycopeptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth observed in the historical period can be attributed to the escalating issue of antibiotic resistance, a rising incidence of infectious diseases, government initiatives, increased healthcare expenditure, and the globalization of infectious diseases.

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period can be attributed to the emergence of infectious diseases, a growing geriatric population, persistent challenges related to antibiotic resistance, increased research and development investments and innovations, and the expansion of healthcare infrastructure. Major trends expected in the forecast period include the continued rise of antibiotic resistance, advancements in research and development, the impact of global health emergencies driving demand, collaborations for antibiotic stewardship, and market expansion in emerging economies.

The glycopeptide antibiotics market is anticipated to witness growth, driven by the increasing number of cancer and infectious disease cases. Cancer, characterized by uncontrolled cell multiplication and spread, and infectious diseases caused by various organisms such as bacteria, viruses, fungi, or parasites, are significant contributors to the demand for glycopeptide antibiotics. These antibiotics play a crucial role in treating infectious disorders caused by bacteria resistant to beta-lactams and other antibiotics. Additionally, in cancer patients, glycopeptide antibiotics enhance the antitumor effects of radiotherapy by targeting both the intended cancer cells and distant cancer cells elsewhere in the body. The American Cancer Society reported 1.9 million new cancer cases and 609,360 cancer deaths in the US in 2022. The rising prevalence of these conditions is expected to drive the growth of the glycopeptide antibiotics market.

The glycopeptide antibiotic market is also set to benefit from the increasing prevalence of gram-positive infections, caused by bacteria such as Staphylococcus aureus and Streptococcus pneumoniae. Glycopeptide antibiotics, with their unique mode of action targeting bacterial cell wall formation, are effective against many gram-positive bacteria. For example, according to the UK Health Security Agency's ESPAUR Report 2022-2023, Group A Streptococcus infections rose by 248% in 2022 compared to the previous year. This increase, even compared to pre-pandemic levels, emphasizes the growing prevalence of gram-positive infections and their role in propelling the glycopeptide antibiotic market.

A key trend in the glycopeptide antibiotics market is product innovation, with major companies focusing on developing innovative solutions. Leiden University, in October 2022, discovered new variants of the antibiotic vancomycin, which exhibited enhanced activity against gram-positive bacteria and lower nephrotoxicity compared to commercially used polymyxin antibiotics. This innovation aims to address the limitations of vancomycin, which is effective only against gram-positive strains.

Strategic partnerships are another notable trend in the glycopeptide antibiotics market, with major companies forming collaborations to bring revolutionary antibiotics to specific regions. In March 2022, Cumberland Pharmaceuticals Inc. announced a partnership with Tabuk Pharmaceutical Manufacturing Company to promote the Vibativ (telavancin) injection in the Middle East. Vibativ is crucial for patients with ventilator-associated pneumonia and hospital-acquired pneumonia caused by difficult-to-treat and multidrug-resistant Gram-positive bacterial infections.

In November 2021, ANI Pharmaceuticals Inc. acquired Novitium Pharma for $163.5 million, aiming to enhance its generics business and focus on specialized markets. Further, acquisitions are shaping the market dynamics, with companies seeking to strengthen their positions and expand their capabilities. Novitium Pharma, a new generic pharmaceutical corporation, contributes to ANI Pharmaceuticals Inc.'s growth and development in the pharmaceutical sector.

Major companies operating in the glycopeptide antibiotics market report are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Melinta Therapeutics Inc., Cumberland Pharmaceuticals Inc., Theravance Biopharma Inc., Janssen Global, Bristol-Myers Squibb Company, GSK Plc., Allergan Plc., Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Lytix Biopharma, Alvogen, Eli Lilly and Company, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, Targanta Therapeutics, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc

North America was the largest region in the glycopeptide antibiotics market in 2023. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glycopeptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glycopeptide antibiotics market consists of sales of teicoplanin, telavancin and ramoplanin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r10994

1. Executive Summary

2. Glycopeptide Antibiotics Market Characteristics

3. Glycopeptide Antibiotics Market Trends And Strategies

4. Glycopeptide Antibiotics Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Glycopeptide Antibiotics Market Size and Growth

5.1. Global Glycopeptide Antibiotics Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Glycopeptide Antibiotics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Glycopeptide Antibiotics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Glycopeptide Antibiotics Market Segmentation

6.1. Global Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Vancomycin
Dalbavancin
Oritavancin
Other Drugs
6.2. Global Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Parenteral
Other Routes
6.3. Global Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Skin And Structure Infection
Meningitis
Clostridioides Difficile Infection
Enterocolitis
Other Indications
6.4. Global Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End-Users

7. Glycopeptide Antibiotics Market Regional And Country Analysis

7.1. Global Glycopeptide Antibiotics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Glycopeptide Antibiotics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Glycopeptide Antibiotics Market

8.1. Asia-Pacific Glycopeptide Antibiotics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Glycopeptide Antibiotics Market

9.1. China Glycopeptide Antibiotics Market Overview
9.2. China Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Glycopeptide Antibiotics Market

10.1. India Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Glycopeptide Antibiotics Market

11.1. Japan Glycopeptide Antibiotics Market Overview
11.2. Japan Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Glycopeptide Antibiotics Market

12.1. Australia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Glycopeptide Antibiotics Market

13.1. Indonesia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Glycopeptide Antibiotics Market

14.1. South Korea Glycopeptide Antibiotics Market Overview
14.2. South Korea Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Glycopeptide Antibiotics Market

15.1. Western Europe Glycopeptide Antibiotics Market Overview
15.2. Western Europe Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Glycopeptide Antibiotics Market

16.1. UK Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Glycopeptide Antibiotics Market

17.1. Germany Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Glycopeptide Antibiotics Market

18.1. France Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Glycopeptide Antibiotics Market

19.1. Italy Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Glycopeptide Antibiotics Market

20.1. Spain Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Glycopeptide Antibiotics Market

21.1. Eastern Europe Glycopeptide Antibiotics Market Overview
21.2. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Glycopeptide Antibiotics Market

22.1. Russia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Glycopeptide Antibiotics Market

23.1. North America Glycopeptide Antibiotics Market Overview
23.2. North America Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Glycopeptide Antibiotics Market

24.1. USA Glycopeptide Antibiotics Market Overview
24.2. USA Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Glycopeptide Antibiotics Market

25.1. Canada Glycopeptide Antibiotics Market Overview
25.2. Canada Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Glycopeptide Antibiotics Market

26.1. South America Glycopeptide Antibiotics Market Overview
26.2. South America Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Glycopeptide Antibiotics Market

27.1. Brazil Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Glycopeptide Antibiotics Market

28.1. Middle East Glycopeptide Antibiotics Market Overview
28.2. Middle East Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Glycopeptide Antibiotics Market

29.1. Africa Glycopeptide Antibiotics Market Overview
29.2. Africa Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Glycopeptide Antibiotics Market Competitive Landscape And Company Profiles

30.1. Glycopeptide Antibiotics Market Competitive Landscape
30.2. Glycopeptide Antibiotics Market Company Profiles
- 30.2.1. ANI Pharmaceuticals Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Fresenius SE & Co. KGaA
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Pfizer Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Mylan N.V.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Glycopeptide Antibiotics Market Competitive Benchmarking

32. Global Glycopeptide Antibiotics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Glycopeptide Antibiotics Market

34. Glycopeptide Antibiotics Market Future Outlook and Potential Analysis

34.1 Glycopeptide Antibiotics Market In 2028 - Countries Offering Most New Opportunities
34.2 Glycopeptide Antibiotics Market In 2028 - Segments Offering Most New Opportunities
34.3 Glycopeptide Antibiotics Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer